FDA product code JBI: Glucose-6-Phosphate Dehydrogenase (Erythrocytic), Catalase Inhibition
JBI is the FDA product code for glucose-6-phosphate dehydrogenase (erythrocytic), catalase inhibition. It is a Class II device, regulated under 21 CFR 864.7360 and reviewed by the Hematology panel. Devices under JBI reach the market by 510(k); FDA lists no cleared 510(k)s for it.
Classification
| Field | Value |
|---|---|
| Device name | Glucose-6-Phosphate Dehydrogenase (Erythrocytic), Catalase Inhibition |
| Device class | Class II |
| Regulation | 21 CFR 864.7360 |
| Review panel | HE — Hematology |
| Medical specialty | Hematology |
| Premarket route | 510(k) |
| Third-party 510(k) review eligible | Yes |
Recalls for JBI devices
FDA recall records list no recalls for product code JBI.
Frequently asked questions
What is FDA product code JBI?
JBI is the FDA product code for glucose-6-phosphate dehydrogenase (erythrocytic), catalase inhibition. It is a Class II device, regulated under 21 CFR 864.7360 and reviewed by the Hematology panel.
What device class is JBI?
Class II, regulation 21 CFR 864.7360. Typical premarket route: 510(k).
Next steps
- Run an FDA pathway report with predicate devices for product code JBI
- Run a recall and safety report across every JBI manufacturer
- Watch product code JBI for new clearances and recalls
Compiled by Caduvo from public U.S. FDA records. Applicant names are shown as FDA records them. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA. Not regulatory advice. Report an error. Data and corrections policy.
All Hematology product codes · FDA product code lookup · 510(k) database search · 510(k) review times